Articles From: IGI Laboratories, Inc. Acquires Eighteen Former Products From AstraZeneca to IGT Inspires The Gaming World To "Laugh.Dance.Play." With The Ellen DeGeneres Show™ Video Slots


2014/9/25
BUENA, N.J. , Sept.
Sign-up for IGI Laboratories, Inc. Acquires Eighteen Former Products From AstraZeneca investment picks
2014/10/1
BUENA, N.J. , Oct.
Sign-up for IGI Laboratories, Inc. Acquires Two Products From Valeant Pharmaceuticals investment picks
BUENA, N.J. , Nov.
Sign-up for IGI Laboratories, Inc. Announces ANDA Submission investment picks
2014/10/9
BUENA, N.J. , Oct.
Sign-up for IGI Laboratories, Inc. Appoints Steven Koehler To Board Of Directors investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977032001&sourceType=1 http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Announces October 2014 Mutual Fund Sales and Total Assets Under Management investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971154001&sourceType=1 http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Announces September 2014 Mutual Fund Sales and Total Assets Under Management investment picks
2014/11/6
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0976817001&sourceType=1 http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Reports Third Quarter Earnings: Increases Dividend investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0972325001&sourceType=1 http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. to Release Third Quarter 2014 Results investment picks
Ignite Restaurant Group (NASDAQ:IRG) today reported financial results for the third quarter ended September 29, 2014.
Sign-up for Ignite Restaurant Group Reports Third Quarter 2014 Financial Results investment picks
Ignite Restaurant Group, Inc. (NASDAQ:IRG) today announced that it will host a conference call to discuss third quarter 2014 financial results on Wednesday, October 29, 2014 at 5:00 PM Eastern Time.
Sign-up for Ignite Restaurant Group, Inc. to Announce Third Quarter 2014 Results on October 29, 2014 investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.
Sign-up for Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for presentation in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO), which is being held from September 26-30, 2014 in Madrid, Spain.
Sign-up for Ignyta Announces RXDX-101 Phase I Data Presentation at the 2014 ESMO Congress investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Sign-up for Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR ‘Molecular Targets and Cancer Therapeutics’ Conference investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2014.
Sign-up for Ignyta Announces Third Quarter 2014 Company Highlights and Financial Results investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Robert Wild, Ph.D., has been appointed as Chief Scientific Officer and Senior Vice President, Research.
Sign-up for Ignyta Appoints Robert Wild, Ph.D., as Chief Scientific Officer and Senior Vice President, Research investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it has secured a $31 million term loan facility from Silicon Valley Bank.
Sign-up for Ignyta Secures $31 Million Term Loan Facility from Silicon Valley Bank investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chief Medical Officer, Adrian Senderowicz, M.D., has been selected to serve as Workshop Planning Committee Chair for the workshop entitled Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer .
Sign-up for Ignyta to Chair the Institute of Medicine’s National Cancer Policy Forum Workshop on Molecularly Targeted Cancer Therapies investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it will host a Key Opinion Leader Breakfast on Tuesday, October 14, 2014 from 8:00-9:30 a.m. Eastern time in New York City.
Sign-up for Ignyta to Host Investor Meeting with Oncology Key Opinion Leaders on October 14, 2014 investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
Sign-up for Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Jacob Chacko, M.D., Chief Financial Officer, will make a presentation at the Livingston Securities Life Science Stakeholders Summit on October 1, 2014 at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) in Philadelphia, PA.
Sign-up for Ignyta to Present at Livingston Securities Life Science Stakeholders Summit investment picks
Ignyta, Inc. (Nasdaq: RXDX), an precision oncology biotechnology company, announced today that it will release its third quarter 2014 financial results after the market closes on Friday, November 7, 2014.
Sign-up for Ignyta to Report 2014 Third Quarter Company Highlights and Financial Results and Host Conference Call on November 7, 2014 investment picks
STRATFORD, Conn.
Sign-up for Igor Sikorsky's VS-300 Helicopter Transformed Aviation 75 Years Ago investment picks
LAS VEGAS , Sept.
Sign-up for IGT and GTECH Amend Merger Agreement investment picks
Central Florida's Premier Entertainment Destination First to Showcase IGT's Sizzling S3000 LAS VEGAS , Nov.
Sign-up for IGT and Seminole Hard Rock Hotel & Casino Tampa Light Up the Gaming World with S3000 Cabinet investment picks
2014/10/8
LAS VEGAS , Oct.
Sign-up for IGT Announces Consent Solicitation for $1.3 Billion of Notes Due 2019, 2020 and 2023 investment picks
LAS VEGAS , Sept.
Sign-up for IGT Brings Las Vegas-Style Excitement and Innovation to Croc's Casino Costa Rica investment picks
LAS VEGAS , Sept.
Sign-up for IGT Expands Jackpot Legacy with MegaHits in Maryland investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: IGI Laboratories, Inc. Acquires Eighteen Former Products From AstraZeneca to IGT Inspires The Gaming World To "Laugh.Dance.Play." With The Ellen DeGeneres Show™ Video Slots
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent